The meeting notice, briefing documents, voting questions and transcript show what a panel was asked and how it answered. A worksheet for comparing that record with FDA's decision.
What the record can tell you
An FDA advisory committee meeting leaves a public trail: a notice in the Federal Register, a meeting page linked from the agency's advisory committee calendar, background material, the questions put to the panel and, later, a transcript. Read together, those documents show what the agency asked its outside advisers and how they answered.
They can't tell you what FDA will decide. In the agency's own meeting notices, a committee's general function is to "provide advice and recommendations to FDA on regulatory issues". The decision belongs to FDA, and it can rest on reasoning the panel never discussed. So the comparison worth making is between the questions on the record and the basis of the decision that follows.
Expect days of notice, and spend them reading. FDA says it publishes meeting announcements in the Federal Register at least 15 calendar days before a meeting and intends to post background material no later than two business days before. Transcripts are generally available within 90 days.
Where each document sits and what it can't settle
Each meeting has its own page, and the documents arrive in a fairly steady order. Copy the table below into your notes and fill the middle column as each piece appears.
| Document | When FDA says it appears | What to copy | What it can't settle |
|---|---|---|---|
| Federal Register notice | At least 15 calendar days before the meeting | Committee, date, application number, sponsor, docket number, comment deadlines | Which questions the panel will vote on |
| Meeting page on the advisory committee calendar | Before the meeting, updated afterward | Links to materials, roster, webcast details, any late changes | Whether the plan held; FDA says last-minute changes may not reach the Federal Register in time |
| Background (briefing) material | No later than two business days before, or at the meeting if FDA can't post it sooner | Each reviewer's analysis in their own words, the sponsor's case, and where they disagree | How the panel will weigh the evidence |
| Discussion and voting questions | Check the meeting page and the transcript for the final wording | The exact question each vote answered | Questions FDA may weigh later |
| Open public hearing | During the meeting | Who spoke and the affiliations they disclosed | How patients in general view the drug |
| Transcript and vote record | Transcripts generally within 90 days | Tallies, each member's stated reasoning, quotable passages | The agency's final decision |
| FDA's decision and any explanation | After the meeting, on the agency's own timeline | Pathway, conditions, and whether FDA addresses the committee's advice | Whether the decision answers the question the panel voted on |
Timing per FDA's common questions about advisory committee meetings. Posting practice varies by meeting, so check each meeting's page.
A worked case: aducanumab, 2020 to 2021
The aducanumab record shows why the wording of a question matters as much as the tally.
On September 29, 2020, FDA announced in the Federal Register that its Peripheral and Central Nervous System Drugs Advisory Committee would meet on November 6 to discuss Biogen's application for aducanumab to treat Alzheimer's disease. The background material went up on Wednesday, November 4, two days ahead. STAT reported that it described one trial's results as "robust and exceptionally persuasive," while the agency's statistical reviewer wrote that "there is no compelling, substantial evidence of treatment effect or disease slowing."
The panel voted on four questions. On the last, whether it was reasonable to treat the one positive study as primary evidence of effectiveness, the vote was 0 yes, 10 no and 1 uncertain, according to Biogen's announcement that day.
On June 7, 2021, FDA approved the drug through the Accelerated Approval pathway, based on its effect on amyloid beta plaque, a surrogate endpoint, and required a post-approval trial to verify clinical benefit. In the statement explaining the decision, Patrizia Cavazzoni, director of FDA's Center for Drug Evaluation and Research, wrote: "The option of Accelerated Approval was not discussed by the Advisory Committee."
Anyone holding the voting questions could see the gap. The panel answered whether one trial established effectiveness. The approval rested on a different standard. Public documents supported that comparison on the day of the decision, and the worksheet below is built to make it.
Copy this advisory committee worksheet
Keep one worksheet per meeting. Fill the first six rows before the decision and the last three after it. The example column uses the aducanumab record.
| Field | What to record | Example (aducanumab) |
|---|---|---|
| Meeting | Committee, date, Federal Register notice and its date | PCNS Drugs Advisory Committee, November 6, 2020; notice published September 29, 2020 |
| Application | Application number, sponsor, proposed use | BLA 761178, Biogen, Alzheimer's disease |
| Material posted | Date the background material appeared and which documents it included | Wednesday, November 4, 2020 |
| Reviewer positions | Each reviewer's conclusion, quoted with document and page | Statistical review: "no compelling, substantial evidence of treatment effect or disease slowing" |
| Voting questions | Exact wording of each question | Four questions; the last asked whether Study 302 could be primary evidence of effectiveness |
| Tallies | Yes, no and uncertain (or abstain) for each question | Last question: 0 yes, 10 no, 1 uncertain |
| Decision | Date, pathway, conditions | June 7, 2021; Accelerated Approval; post-approval trial required |
| Match check | Does the decision rest on a question the panel answered? | No. FDA said Accelerated Approval was not discussed by the committee |
| Open questions | What you'd ask FDA, the sponsor or an independent specialist | Your own |
Sources for the example column are linked in the worked case above.
Keep the record separate from advice
Quote reviewers by role and document, and keep the sponsor's sections apart from FDA's. A reviewer's dissent is one reviewer's analysis. A vote records how the members present answered a specific question on a specific day. Neither tells a reader whether to take a drug.
When the basis of a decision differs from the question the panel answered, report the difference and ask the agency to explain it before you offer a reason. The ClinicalTrials.gov guide covers the trial registry behind the analyses in a briefing document, and the reported-angle worksheet helps narrow a claim to what the record supports.
Leave treatment decisions to clinicians
A panel vote or a reviewer's dissent is a record of a regulatory argument. Attribute it to the document, link the meeting page, and send readers to their clinician for treatment decisions.
Following a health field between meetings
Advisory meetings are occasional, and coverage around a decision moves quickly. A Niche briefing follows a field you describe, checks coverage against independent sources and links them, so a story about a panel or an approval arrives with its sources attached. The record check stays manual: open the meeting page, fill the worksheet and decide what your readers need to know.
Frequently asked questions
Where do I find upcoming FDA advisory committee meetings?
On FDA's advisory committee calendar, which links each meeting's page, and in the Federal Register, where FDA says announcements appear at least 15 calendar days before a meeting. Last-minute changes may not reach the Federal Register in time, so check the meeting page.
How early are FDA briefing documents posted?
FDA says it intends to post background material no later than two business days before a meeting. If it can't, the material is made available at the meeting. Transcripts are generally available within 90 days.
Does FDA have to follow an advisory committee's vote?
Committees give advice and recommendations, and FDA makes the decision. In 2021 FDA approved aducanumab through Accelerated Approval after the committee voted 10 no, 0 yes and 1 uncertain on treating the one positive trial as primary evidence of effectiveness. FDA said the committee had not discussed Accelerated Approval.